OGN
Organon & Co.
Set alert
- YTD
- +93.03%
- 1 year
- +110.65%
- Open
- 13.83
- Prev close
- 13.81
- Mkt cap
- 3.63B
- Vol
- 1.85M
- Avg vol
- 2.59M
- EPS
- 0.78
- P/E
- 17.74
- Div yield
- 0.58%
More statistics
- Low
- 13.81
- High
- 13.84
- Forward P/E
- 3.79
- Beta
- 1.54
- Short ratio
- 8.54
- Inst. own
- 84.60%
- Dividend
- 0.08
- Ex-div date
- Aug 13, 2026
- 50-d avg
- 13.74
- 200-d avg
- 11.49
- 1y target
- 10.33
Key statistics
- Market cap
- 3.63B
- Enterprise value
- 11.05B
- Trailing P/E
- 17.74
- Forward P/E
- 3.79
- PEG ratio
- 0.00
- Price / sales
- 0.59
- Price / book
- 3.61
- EPS (TTM)
- 0.78
- Beta
- 1.54
- Dividend yield
- 0.58%
- Payout ratio
- 10.26%
- Profit margin
- 3.41%
- Revenue (TTM)
- 6.13B
- Revenue growth
- -2.30%
- Free cash flow
- 490.75M
- Total cash
- 1.13B
- Total debt
- 8.55B
- Return on equity
- 24.04%
- Shares outstanding
- 262.61M
- Short % of float
- 8.15%
- 50-day average
- 13.74
- 200-day average
- 11.49
Analyst view
Consensus: hold
- Target (low)
- 8.00
- Target (mean)
- 10.33
- Target (high)
- 14.00
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate 0.94645.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.88 | 0.94 | +0.06 | +6.82% |
| Jul 31, 2026 | Jun 30, 2026 | 0.85 | 0.85 | 0.00 | 0.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.83 | 0.71 | -0.12 | -14.46% |
| Feb 12, 2026 | Dec 31, 2025 | 0.73 | 0.63 | -0.10 | -13.70% |
| Nov 10, 2025 | Sep 30, 2025 | 0.93 | 1.01 | +0.08 | +8.60% |
| Aug 5, 2025 | Jun 30, 2025 | 0.94 | 1.00 | +0.06 | +6.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | down | Outperform | Neutral |
| Apr 28, 2026 | Piper Sandler | up | Underweight | Neutral |
| Feb 24, 2026 | Barclays | main | Underweight | Underweight |
| Dec 9, 2025 | Barclays | init | — | Underweight |
| Nov 11, 2025 | JP Morgan | main | Underweight | Underweight |
| Nov 11, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- organon.com
News
- Organon (OGN) Q3 Earnings and Revenues Top Estimates
- Organon Announces Quarterly Dividend
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
- Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
- Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
- Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
- Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
- Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold
- Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia
Your note
Sign in to keep a note on OGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI KEVIN | Chief Executive Officer | Purchase | May 4, 2025 | 282,731 |
| COX CARRIE SMITH | Officer and Director | Purchase | Nov 11, 2025 | 0 |
| FALCIONE AARON | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 101,431 |
| HOLZBAUR LYNETTE | Officer | Purchase | May 5, 2026 | 52,850 |
| KARP DANIEL | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 69,547 |
| MORRISSEY JOSEPH T JR | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 123,123 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.21% | 32,056,866 | 443.67M | Jun 29, 2026 |
| Pentwater Capital Management Lp | 6.89% | 18,100,000 | 250.50M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.76% | 15,132,118 | 209.43M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.54% | 11,909,865 | 164.83M | Jun 29, 2026 |
| State Street Corporation | 3.68% | 9,659,371 | 133.69M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 1.98% | 5,199,002 | 71.95M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 15,638,261 | 216.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,332,789 | 115.33M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 6,024,699 | 83.38M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 3,815,001 | 52.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 3,010,255 | 41.66M | Jun 29, 2026 |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 1.03% | 2,705,080 | 37.44M | Jun 29, 2026 |